S701
Clinical – Lower GI
ESTRO 2026
Buglione di Monale e Bastia 2 , Filippo Alongi 1 , Mattia Falchetto Osti 3 1 Department of Advanced Radiation Oncology, IRCCS SacroCuore Don Calabria Hospital, Cancer Care Center, Negrar di Valpolicella, Italy. 2 Radiation Oncology Department, ASST Spedali Civili di Brescia - Brescia University, Brescia, Italy. 3 Department of Radiation Oncology, "Sapienza" University, Sant'Andrea Hospital, Rome, Italy. 4 Clinical Analysis Laboratory and Transfusional Medicine, IRCCS SacroCuore Don Calabria Hospital, Cancer Care Center, Negrar di Valpolicella, Italy. 5 Department of Information Engineering, University of Padova, Padova, Italy. 6 Radiation Oncology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. 7 Division of Radiation Oncology, Department of Translational Medicine, University of Eastern Piedmont, and University Hospital "Maggiore della Carità", Novara, Italy. 8 Department of Radiation Oncology, Justus- Liebig-University Giessen, Giessen-Marburg University Hospital, Giessen, Germany. 9 UOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. 10 Department of Radiation Oncology, Cancer Institute, Imam-Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of. 11 Radiation Oncology Department, AST Pesaro Urbino, Pesaro, Italy. 12 Radiation Oncology, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Rome, Italy. 13 Radiotherapy Unit, San Martino Hospital, Belluno, Italy. 14 Department of Radiation Therapy, Centre Eugène Marquis, Rennes, France. 15 Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, Italy Purpose/Objective: Preoperative radiochemotherapy (RCHT) is the standard treatment for locally advanced rectal cancer (LARC).The evidence that pathological complete response (pCR) is a favorable independent prognostic factor for overall survival (OS) leads to investigate the role of RCHT intensification. While strong evidence demonstrated the role of intensified chemotherapy (CHT), few data documented the effect of intensified radiotherapy (RT) on survival. This study aims to estimate the effects of different RT dose level on
Conclusion: In TNT with consolidation chemotherapy for LARC (UICC II/III), CR was similar between women and men, whereas acute high-grade toxicity, notably gastrointestinal and haematologic, was consistently higher in women. No differences in short-term survival were observed. These findings support a toxicity risk assessment that considers sex differences, as well as a prospective evaluation of tailored supportive care, dose modulation, and monitoring, all of which can be achieved while maintaining comparable tumour control. Keywords: total neoadjuvant therapy, sex-specific outcomes Analysis of pATients with Locally Advanced rectal caNcer given neoadjuvanT radiochemotherapy with or without RT dose IntenSification: ATLANTIS II Luca Nicosia 1 , Marco Lorenzo Bonù 2 , Ilaria Angelicone 3 , Gianluigi Lunardi 4 , Annaluce Massignan 5 , Rita Marina Niespolo 6 , Micol Zannetti 7 , Linda Agolli 8 , Giuditta Chiloiro 9 , Angela Romano 9 , Fatemeh Jafari 10 , Mariangela La Macchia 11 , Francesca De Felice 12 , Filippo De Renzi 13 , Jennifer Le Guevelou 14 , Marco Lupattelli 15 , Giuseppe Minniti 12 , Giampaolo Montesi 11 , Maria Antonietta Gambacorta 9 , Daniel Habermehl 8 , Pierfrancesco Franco 7 , Stefano Arcangeli 6 , Michela Poster Discussion 1811
survival endpoints. Material/Methods:
Data from 12 centers were collected for the current large retrospective study (Prog. 3774CESC). Primary end-point was overall survival (OS). Secondary end- points were metastases-free survival (MFS) and disease-free survival (DFS) A predictive model was developed to estimate the effect of different factors on
Made with FlippingBook - Share PDF online